Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Announcement 15/2/21
stale
Added 3 years ago

Cancer Conference Presentation Confirms Potential Breakthrough For Stage 4 Prostate Cancer Patients

• Drug combination NOX66 (Veyonda?) and 177lutetium-PSMA-617 delivers high response rates in heavily pre-treated men with end-stage prostate cancer

• Median Overall Survival of 19.7 months a potential breakthrough in the treatment of end-stage prostate cancer

View Attachment

Read More